BMO Capital raised the firm’s price target on Gilead (GILD) to $130 from $120 and keeps an Outperform rating on the shares. The company’s Q2 print provided a breath of fresh air with a clean beat and raise, coupled with bullish commentary on the ongoing launch of Yeztugo, the analyst tells investors in a research note. BMO adds that it remains positive on Gilead shares into the back half of the year with what should be a strong start to the launch of Yeztugo and iMMagine-1 data expected by 2025-end.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $143 from $135 at Morgan Stanley
- Assembly Biosciences reports interim results from phase 1b study of ABI-5366
- Gilead price target raised to $112 from $108 at UBS
- Gilead upgraded to Buy from Hold at Truist
- Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating